POL Scientific / Bladder / Volume 12 / Issue 1 / DOI: 10.14440/bladder.2024.0034
Submit to Bladder
Cite this article
9
Download
32
Citations
223
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
RESEARCH ARTICLE

Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients

Fernando Korkes1* ,  José Henrique DallAcqua Santiago1 ,  André Marantes Masciarelli Pinto1 ,  Artur da Silva Farias1 ,  Frederico Timóteo1 ,  Suelen Patricia dos Santos Martins1 ,  Sidney Glina1
Show Less
1 Division of Urology, Centro Universitario FMABC, Santo Andre, São Paulo 09060-650, Brazil
Bladder 2025 , 12(1), e21200027; https://doi.org/10.14440/bladder.2024.0034
Submitted: 5 June 2024 | Revised: 26 June 2024 | Accepted: 11 July 2024 | Published: 3 March 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease typically treated with radical cystectomy following neoadjuvant chemotherapy (NAC). However, the presence of hydronephrosis – a significant marker of advanced disease – can impair renal function, potentially precluding patients from receiving cisplatin-based NAC. Objective: The present study aimed to assess the role of urinary diversion in patients with MIBC, specifically in reversing renal function impairment and enabling eligibility for cisplatin-based therapy. Methods: A retrospective study was performed by evaluating a database of patients treated for urothelial MIBC from 2018 to 2021. Case notes were reviewed to identify patients with hydronephrosis who underwent urinary diversion. The types of urinary diversion recorded included percutaneous nephrostomy, ureteral stenting, or surgical obstruction release. Renal function was assessed retrospectively using the glomerular filtration rate (GFR), estimated from creatinine clearance. Results: Records of a total of 72 patients were evaluated. The mean GFR before urinary diversion was 44.1 ± 26.4 mL/min, which improved to 59.1 ± 31.9 mL/min post-diversion, resulting in a mean GFR improvement of 15.0 ± 20.0 mL/min. Forty-four patients had an initial GFR below 50 mL/min, with 75% of them achieving a GFR >50 mL/min after urinary diversion. More than half of these patients (n = 25, 56%) experienced an improvement to a GFR exceeding 60 mL/min. The time to reach the best GFR varied widely (mean: 59 ± 33 days, range 9 – 165 days). Logistic regression analysis identified initial GFR as a significant predictor of GFR recovery (odds ratio = 1.11, 95% confidence interval = 1.02 – 1.21, p = 0.012). Conclusion: Urinary diversion can benefit patients with upper tract obstruction secondary to MIBC by improving renal function, thereby enabling eligibility for cisplatin-based chemotherapy. Notably, the time to GFR recovery following urinary diversion varied among individuals.

Keywords
Urothelial cancer
Bladder neoplasm
Nephrostomy
Ureteral stent
Urinary diversion
Renal insufficiency
Cisplatin
Neoadjuvant chemotherapy
Funding
None.
References
  1. Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055

 

  1. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-2177. doi: 10.1200/JCO.2010.32.3139

 

  1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published correction appears in N Engl J Med. 2003;349(19):1880]. N Engl J Med. 2003;349(9):859-866. doi: 10.1056/NEJMoa022148

 

  1. Hamid ARA, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 2020;20(1):158. doi: 10.1186/s12894-020-00733-z

 

  1. Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from the National Cancer Database. Urology. 2014;83(1):75-80. doi: 10.1016/j.urology.2013.07.072

 

  1. Korkes F. Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients. Int Braz J Urol. 2021;47(4):819-820. doi: 10.1590/S1677-5538.IBJU.2020.0594.1

 

  1. Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol. 2012;30(6):772-780. doi: 10.1016/j.urolonc.2012.01.012

 

  1. Thompson RH, Boorjian SA, Kim SP, et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014;113(5b):E17-E21. doi: 10.1111/bju.12274

 

  1. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506-513. doi: 10.1002/cncr.22031

 

  1. Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol. 2007;51(3):690-698. doi: 10.1016/j.eururo.2006.07.009

 

  1. Greiner R, Skaleric C, Veraguth P. The prognostic significance of ureteral obstruction in carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1977;2(11-12):1095-1100. doi: 10.1016/0360-3016(77)90115-8

 

  1. Bowles WT, Silber I. Carcinoma of the bladder: A computer analysis of 516 patients. J Urol. 1972;107(2):245-247. doi: 10.1016/s0022-5347(17)60993-5

 

  1. Leibovitch I, Ben-Chaim J, Ramon J, Madjar I, Engelberg IS, Goldwasser B. The significance of ureteral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol. 1993;52(1):31-35. doi: 10.1002/jso.2930520109

 

  1. Khalaf IM, Shokeir AA, El-Gyoushi FI, Amr HS, Amin MM. Recoverability of renal function after treatment of adult patients with unilateral obstructive uropathy and normal contralateral kidney: A prospective study. Urology. 2004;64(4):664-668. doi: 10.1016/j.urology.2004.05.018

 

  1. Better OS, Arieff AI, Massry SG, Kleeman CR, Maxwell MH. Studies on renal function after relief of complete unilateral ureteral obstruction of three months’ duration in man. Am J Med. 1973;54(2):234-240. doi: 10.1016/0002-9343(73)90228-3

 

  1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi: 10.1159/000180580

 

  1. Pal SK, Ruel N, Villegas S, et al. CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. PLoS One. 2014;9(4):e94471. doi: 10.1371/journal.pone.0094471

 

  1. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708-715. doi: 10.1634/theoncologist.2015-0440

 

  1. North S. Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? Can Urol Assoc J. 2008;2(3):222-224. doi: 10.5489/cuaj.602

 

  1. Li G, Niu HM, Wu HT, et al. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: A meta-analysis. Clin Invest Med. 2017;40(2):E81-E94. doi: 10.25011/cim.v40i2.28199

 

  1. Sternberg CN. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol. 2007;34(2):122-128. doi: 10.1053/j.seminoncol.2006.12.006

 

  1. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS, Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: Results from a surveillance, epidemiology, and end results-medicare analysis. Cancer. 2009;115(5):988-996. doi: 10.1002/cncr.24052

 

  1. Seah JA, Blais N, North S, et al. Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Can Urol Assoc J. 2013;7(9-10):312-318. doi: 10.5489/cuaj.1506

 

  1. Kaeidi A, Maleki M, Shamsizadeh A, Fatemi I, Hakimizadeh E, Hassanshahi J. The therapeutic approaches of renal recovery after relief of the unilateral ureteral obstruction: A comprehensive review. Iran J Basic Med Sci. 2020;23(11):1367-1373. doi: 10.22038/ijbms.2020.41984.9926

 

  1. Cochrane AL, Kett MM, Samuel CS, et al. Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol. 2005;16(12):3623-3630. doi: 10.1681/ASN.2004090771

 

  1. Ito K, Chen J, El Chaar M, et al. Renal damage progresses despite improvement of renal function after relief of unilateral ureteral obstruction in adult rats. Am J Physiol Renal Physiol. 2004;287(6):F1283-F1293. doi: 10.1152/ajprenal.00441.2003

 

  1. Fink RL, Caridis DT, Chmiel R, Ryan G. Renal impairment and its reversibility following variable periods of complete ureteric obstruction. Aust N Z J Surg. 1980;50(1):77-83. doi: 10.1111/j.1445-2197.1980.tb04502.x

 

  1. Fallon B. Functional recovery in a kidney after prolonged, complete ureteric obstruction. Br J Urol. 1977;49(1):72. doi: 10.1111/j.1464-410x.1977.tb04527.x

 

  1. Shapiro SR, Bennett AH. Recovery of renal function after prolonged unilateral ureteral obstruction. J Urol. 1976;115(2):136-140. doi: 10.1016/s0022-5347(17)59101-6

 

  1. Earlam RJ. Recovery of renal function after prolonged ureteric obstruction. Br J Urol. 1967;39(1):58-62. doi: 10.1111/j.1464-410x.1967.tb11784.x

 

  1. Brunschwig A, Barber HR, Roberts S. Return of renal function after varying periods of ureteral occlusion. A clinical study. JAMA. 1964;188:5-8. doi: 10.1001/jama.1964.03060270011002

 

  1. Graham JB. Recovery of kidney after ureteral obstruction. JAMA. 1962;181:993-994. doi: 10.1001/jama.1962.03050370061017
Conflict of interest
The authors declare no conflicts of interest.
Share
Back to top
Bladder, Electronic ISSN: 2327-2120 Print ISSN: TBA, Published by POL Scientific
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept